Exclusive Webinar :Gain complete knowledge about how you can invest in global markets during an insightful webinar on April 16 at 11 am. Register Now!
you are here: HomeNewsBusiness

Cipla gets USFDA nod for migraine drug

The newly approved product is a generic therapeutic equivalent version of GlaxoSmithKline's Imitrex Nasal Spray.

March 02, 2021 / 10:10 AM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug major Cipla on Tuesday said it has received final approval from the United States Food and Drug Administration (USFDA) for Sumatriptan Nasal Spray, indicated for the treatment of migraine attacks.

The newly approved product is a generic therapeutic equivalent version of GlaxoSmithKline's Imitrex Nasal Spray.

The company has received final approval for its abbreviated new drug application (ANDA) for Sumatriptan Nasal Spray, 20 mg from the United States Food and Drug Administration (USFDA), Cipla said in a regulatory filing.

Quoting IQVIA (IMS Health) data, Cipla said Imitrex Nasal Spray 20mg and its generic equivalents had US sales of approximately USD 53.3 million for the 12-month period ending December 2020.

Shares of Cipla were trading 0.88 percent higher at Rs 796.45 apiece on BSE.
PTI
first published: Mar 2, 2021 10:11 am

stay updated

Get Daily News on your Browser
Sections